July 27, 2021
The Inaugural staging of CanEx Psychedelics Summit was hosted at the Jewel Grande Montego Bay Resort in Montego Bay, St. James, Jamaica from July 15-16.
Trinidadian-born Douglas Gordon, Founder of CanEx Jamaica and CEO of Silo Wellness – a vertical Mushroom company that grows its mushroom in Jamaica – said that he felt it necessary for the discussion surrounding the emerging industry needed to start in Jamaica.
Jamaica is one of the few places where producing magic mushrooms is still legal and is also one of two locations – the other being Oregon- where Silo Wellness hosts its mushroom retreats.
Psychedelics are a class of hallucinogenic substances that produce changes in perception, mood, and cognitive processes of which include magic mushrooms otherwise known as Psilocybin Mushrooms. Researchers say extracts from mushrooms have a strong track record in treating psychiatric and psychosomatic illnesses.
Aion Therapeutic s Dr De La Haye to Speak at the CanEx Psychedelics Summit
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Aion Therapeutic s Dr De La Haye to Speak at the CanEx Psychedelics Summit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Aion Therapeutic s Dr De La Haye to Speak at the CanEx Psychedelics Summit
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)
USA - English
Share this article
Aion Therapeutic Inc. (CSE: AION) (
Aion Therapeutic or the
Company ) announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and methods for producing emulsions and nano-emulsions for increasing bioavailability in these formulations. These new additions increase our intellectual property portfolio to a current total of 9 patent applications with more expected in the very near future.